CCT196969
{[allProObj[0].p_purity_real_show]}
货号：A839302
CCT196969 is active against melanoma and colorectal cancer cell lines that are mutant for BRAF, but not cancer cells that are wild-type for BRAF and NRAS. CCT196969 induces caspase 3 and PARP cleavage, thus induces apoptosis. CCT196969 does not drive paradoxical pathway activation and inhibit MEK/ERK in BRAF and NRAS mutant melanoma.
CCT196969 化学结构
CCT196969 3D分子结构
规格
价格
会员价
库存
数量
{[ item.pr_size ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}
{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}
{[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}
{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}
{[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}
{[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]}
{[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}
现货
咨询
-
+
CCT196969 纯度/质量文件 产品仅供科研
货号：A839302
标准纯度：
{[allProObj[0].p_purity_real_show]}
产品说明书
全球学术期刊中引用的产品
• Nat. Biomed. Eng. , 2024, 8, 1412-1424. Ambeed. A538667 ,
A631746
]
• JMC , 2024. Ambeed. A356070
]
• BMC Cancer , 2024, 24(1): 1415. Ambeed. A209020
]
• J. Am. Soc. Mass Spectrom. , 2024, 35(12): 3192-3202. Ambeed. A961334 ,
A292945 ,
A230770 ,
A300620 ,
A1114580 ,
A1159765 ,
A206238
]
• PloS One , 2024, 19(11): e0308060. Ambeed. 更多 >
CCT196969 质控信息
Encorafenib
✔
99%+
GDC-0879
++++
99%+
SB-590885
++++
99%+
RAF265
99%+
Dabrafenib
++++
B-Raf (V600E), IC50: 0.7 nM
B-Raf, IC50: 5.2 nM
+++
98%
Lifirafenib
++++
++
BRAF WT, IC50: 32 nM
BRAF(V600E), IC50: 23 nM
+++
C-RAF (Y340/341D), IC50: 7 nM
EGFR
98%
ZM 336372
+
99%+
NVP-BHG 712
+
99%+
CCT196969
+
++
Src
98%
Vemurafenib
++
B-Raf (V600E), IC50: 31 nM
B-Raf, IC50: 100 nM
+
98+%
PLX4720
++
B-Raf (V600E), IC50: 13 nM
B-Raf, IC50: 160 nM
+++
C-Raf-1 (Y340D/Y341D), IC50: 6.7 nM
BRK
99+%
GW 5074
+++
99%+
Avutometinib
+++
BRAF, IC50: 19 nM
BRAF V600E, IC50: 8.2 nM
+
98%
LY3009120
++++
BRAF WT, IC50: 15 nM
BRAF(V600E), IC50: 5.8 nM
++++
99%+
Agerafenib
++
B-Raf, Kd: 36 nM
B-Raf (V600E), Kd: 14 nM
+
RET
99%+
TAK-632
+++
++++
99%+
AZ 628
+
B-Raf (V600E), IC50: 34 nM
B-Raf, IC50: 105 nM
++
99%
PLX7904
✔
98+%
Sorafenib
++
B-Raf, IC50: 22 nM
B-Raf (V599E), IC50: 38 nM
++++
++++
99%
Tovorafenib
✔
99%+
展开
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。
CCT196969 生物活性
靶点
Src
Src, IC50:0.03 μM
Lck
LCK, IC50:0.02 μM
B-Raf
BRAF, IC50:0.1 μM
C-Raf/Raf-1
CRAF, IC50:0.01 μM
描述
CCT196969 is active against melanoma and colorectal cancer cell lines that are mutant for BRAF, but not cancer cells that are wild-type for BRAF and NRAS. CCT196969 induces caspase 3 and PARP cleavage, thus induces apoptosis. CCT196969 does not drive paradoxical pathway activation and inhibit MEK/ERK in BRAF and NRAS mutant melanoma.
CCT196969 实验方案
计算器
摩尔计算器
总药量计算器
工作液计算器
存储液制备
1mg
5mg
10mg
1 mM
5 mM
10 mM
1.95mL
0.39mL
0.19mL
9.74mL
1.95mL
0.97mL
19.47mL
3.89mL
1.95mL
CCT196969 技术信息
搜索
